Shigella sonnei vaccines

Drug Profile

Shigella sonnei vaccines

Latest Information Update: 14 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Israel Defense Force; National Institutes of Health (USA); Walter Reed Army Institute of Research
  • Class Bacterial vaccines; Drug conjugates
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Shigella infections

Most Recent Events

  • 16 Apr 2009 Shigella sonnei vaccines complete a phase III trial in Israel
  • 22 Sep 2006 This vaccine is still in active development
  • 06 Oct 2003 A clinical study has been added to the adverse events and Bacterial Infections immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top